{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T04:09:59Z","timestamp":1767499799247,"version":"3.40.5"},"reference-count":10,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2022-0643_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>CHI is a relevant cause of persistent and severe hypoglycemia and the ABCC8 gene mutation is one of most common cause of the disease. Two main types of CHI have been described, diffuse and focal form. Octreotide is a medication utilized in case of diazoxide-unresponsive forms of CHI. For those CHI focal forms where is decided either to manage medically or until resolutive surgery is completed, octreotide can be administered as subcutaneous injection or as continuous subcutaneous infusion via insulin pump. However, it is unclear how to adjust the drug\u2019s daily basal pattern when a pump is used. <\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2022-0643_abs_002\">\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>We present a case of an infant with a diazoxide-unresponsive focal form of CHI, due to ABCC8 mutation ABCC8, treated with octreotide. To better evaluate the glycemic trend, a CGM was placed. In order to achieve a better personalization of the therapy we utilized an insulin pump for octreotide administration. <\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2022-0643_003\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The adoption of the CGM and insulin pump, allowed a better personalization of the therapy and a reduction of acute carbohydrate intake, promoting a good auxological growth before resolutive surgery. What is new? Octreotide administered with an insulin pump in patient with CHI allows a wide modulation of the daily therapy. The CGM allows a continuous and a less painful control of the glycemic trend in a patient with CHI. Different basal rates, given via insulin pump may allow a better personalization of the therapy. Prevention of hypoglycemia reduces the acute introduction of carbohydrates, promoting normal growth..<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2022-0643","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T05:40:35Z","timestamp":1685425235000},"page":"803-807","source":"Crossref","is-referenced-by-count":1,"title":["Adjustment of octreotide dose given via insulin pump based on continuous glucose monitoring (CGM) in a child with congenital hyperinsulinism"],"prefix":"10.1515","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2528-3276","authenticated-orcid":false,"given":"Valentina","family":"Tiberi","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health , Paediatric Diabetology, AOU Ospedali Riuniti di Ancona, G. Salesi Hospital , Ancona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Cherubini","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health , Paediatric Diabetology, AOU Ospedali Riuniti di Ancona, G. Salesi Hospital , Ancona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Iannilli","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health , Paediatric Diabetology, AOU Ospedali Riuniti di Ancona, G. Salesi Hospital , Ancona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gasparini","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health , Paediatric Diabetology, AOU Ospedali Riuniti di Ancona, G. Salesi Hospital , Ancona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health , Paediatric Diabetology, AOU Ospedali Riuniti di Ancona, G. Salesi Hospital , Ancona , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"2023080909320495732_j_jpem-2022-0643_ref_001","doi-asserted-by":"crossref","unstructured":"Rami, B, Mercimek-Mahmutoglu, S, Feucht, M, Herle, M, Rittinger, O, Stoeckler-Ipsiroglu, S, et al.. Long-term follow-up of patients with congenital hyperinsulinism in Austria. J Pediatr Endocrinol Metab 2008;21:523\u201332. https:\/\/doi.org\/10.1515\/jpem-2008-210606.","DOI":"10.1515\/jpem-2008-210606"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_002","doi-asserted-by":"crossref","unstructured":"Yorifuji, T, Kawakita, R, Hosokawa, Y, Fujimaru, R, Matsubara, K, Aizu, K, et al.. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of K ATP -channel hyperinsulinism. Clin Endocrinol 2013;78:891\u20137. https:\/\/doi.org\/10.1111\/cen.12075.","DOI":"10.1111\/cen.12075"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_003","doi-asserted-by":"crossref","unstructured":"Yorifuji, T, Horikawa, R, Hasegawa, T, Adachi, M, Soneda, S, Minagawa, M, et al.. Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol 2017;26:127\u201352. https:\/\/doi.org\/10.1297\/cpe.26.127.","DOI":"10.1297\/cpe.26.127"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_004","doi-asserted-by":"crossref","unstructured":"Demirbilek, H, Shah, P, Arya, VB, Hinchey, L, Flanagan, SE, Ellard, S, et al.. Long-Term follow-up of children with congenital hyperinsulinism on octreotide therapy. J Clin Endocrinol Metab 2014;99:3660\u20137. https:\/\/doi.org\/10.1210\/jc.2014-1866.","DOI":"10.1210\/jc.2014-1866"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_005","doi-asserted-by":"crossref","unstructured":"Glaser, B, Hirsch, HJ, Landau, H. Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr 1993;123:644\u201350. https:\/\/doi.org\/10.1016\/s0022-3476(05)80970-9.","DOI":"10.1016\/S0022-3476(05)80970-9"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_006","doi-asserted-by":"crossref","unstructured":"Ackermann, AM, Palladino, AA. Managing congenital hyperinsulinism: improving outcomes with a multidisciplinary approach. Res\u00a0Rep\u00a0Endocr Disord 2015;5:103\u2013117. https:\/\/doi.org\/10.2147\/rred.s56608.","DOI":"10.2147\/RRED.S56608"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_007","doi-asserted-by":"crossref","unstructured":"Worth, C, Dunne, M, Ghosh, A, Harper, S, Banerjee, I. Continuous glucose monitoring for hypoglycaemia in children: perspectives in 2020. Pediatr Diabetes 2020;21:697\u2013706. https:\/\/doi.org\/10.1111\/pedi.13029.","DOI":"10.1111\/pedi.13029"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_008","doi-asserted-by":"crossref","unstructured":"Burroni, L, Palucci, A, Biscontini, G, Cherubini, V. Early diagnosis of focal congenital hyperinsulinism: a fluorine-18-labeled l-dihydroxyphenylalanine positron emission tomography\/computed tomography study. World J Nucl Med 2021;20:395. https:\/\/doi.org\/10.4103\/wjnm.wjnm_159_20.","DOI":"10.4103\/wjnm.wjnm_159_20"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_009","doi-asserted-by":"crossref","unstructured":"Thornton, PS, Stanley, CA, De Leon, DD, Harris, D, Haymond, MW, Hussain, K, et al.. Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr 2015;167:238\u201345. https:\/\/doi.org\/10.1016\/j.jpeds.2015.03.057.","DOI":"10.1016\/j.jpeds.2015.03.057"},{"key":"2023080909320495732_j_jpem-2022-0643_ref_010","unstructured":"Hussain, K, Aynsley-Green, A, Stanley, CA. Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI). Pediatr Endocrinol Rev 2004;2:163\u20137."}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0643\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0643\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T09:32:45Z","timestamp":1691573565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0643\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,22]]},"published-print":{"date-parts":[[2023,8,28]]}},"alternative-id":["10.1515\/jpem-2022-0643"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2022-0643","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"type":"print","value":"0334-018X"},{"type":"electronic","value":"2191-0251"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}